Opeskin K - Search Results

1

No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas.

Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson ER, Ramakrishna M, Gorringe KL, Polyak K, Haviv I, Campbell IG. Qiu W, et al. Among authors: opeskin k. Nat Genet. 2008 May;40(5):650-5. doi: 10.1038/ng.117. Epub 2008 Apr 13. Nat Genet. 2008. PMID: 18408720 Free PMC article.

2

Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma.

Johnson CE, Gorringe KL, Thompson ER, Opeskin K, Boyle SE, Wang Y, Hill P, Mann GB, Campbell IG. Johnson CE, et al. Among authors: opeskin k. Breast Cancer Res Treat. 2012 Jun;133(3):889-98. doi: 10.1007/s10549-011-1835-1. Epub 2011 Nov 4. Breast Cancer Res Treat. 2012. PMID: 22052326 Free article.

3

Copy number analysis of ductal carcinoma in situ with and without recurrence.

Gorringe KL, Hunter SM, Pang JM, Opeskin K, Hill P, Rowley SM, Choong DY, Thompson ER, Dobrovic A, Fox SB, Mann GB, Campbell IG. Gorringe KL, et al. Among authors: opeskin k. Mod Pathol. 2015 Sep;28(9):1174-84. doi: 10.1038/modpathol.2015.75. Epub 2015 Jun 19. Mod Pathol. 2015. PMID: 26321097 Free article.

4

Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer.

Newnham GM, Conron M, McLachlan S, Dobrovic A, Do H, Li J, Opeskin K, Thompson N, Wright GM, Thomas DM. Newnham GM, et al. Among authors: opeskin k. BMC Cancer. 2011 Mar 7;11:93. doi: 10.1186/1471-2407-11-93. BMC Cancer. 2011. PMID: 21385341 Free PMC article.

5

A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.

Holloway AJ, Diyagama DS, Opeskin K, Creaney J, Robinson BW, Lake RA, Bowtell DD. Holloway AJ, et al. Among authors: opeskin k. Clin Cancer Res. 2006 Sep 1;12(17):5129-35. doi: 10.1158/1078-0432.CCR-06-1027. Clin Cancer Res. 2006. PMID: 16951230

6

Differential expression of VEGF ligands and receptors in prostate cancer.

Woollard DJ, Opeskin K, Coso S, Wu D, Baldwin ME, Williams ED. Woollard DJ, et al. Among authors: opeskin k. Prostate. 2013 May;73(6):563-72. doi: 10.1002/pros.22596. Epub 2012 Oct 4. Prostate. 2013. PMID: 23038639

7

Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.

Zeng Y, Opeskin K, Goad J, Williams ED. Zeng Y, et al. Among authors: opeskin k. Cancer Res. 2006 Oct 1;66(19):9566-75. doi: 10.1158/0008-5472.CAN-06-1488. Cancer Res. 2006. PMID: 17018613

8

Favourable outcome of pulmonary zygomycosis in haematological malignancy.

Opeskin K, Sheorey H, Wright G, Nandurkar H. Opeskin K, et al. Pathology. 2006 Jun;38(3):271-3. doi: 10.1080/00313020600699169. Pathology. 2006. PMID: 16753758 No abstract available.

9

Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab.

Chaiwatanatorn K, Stamaratis G, Opeskin K, Firkin F, Nandurkar H. Chaiwatanatorn K, et al. Among authors: opeskin k. Leuk Lymphoma. 2009 Oct;50(10):1666-75. doi: 10.1080/10428190903165233. Leuk Lymphoma. 2009. PMID: 19757311

10

Vascular endothelial growth factor receptor-3 directly interacts with phosphatidylinositol 3-kinase to regulate lymphangiogenesis.

Coso S, Zeng Y, Opeskin K, Williams ED. Coso S, et al. Among authors: opeskin k. PLoS One. 2012;7(6):e39558. doi: 10.1371/journal.pone.0039558. Epub 2012 Jun 22. PLoS One. 2012. PMID: 22745786 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

95 results

Search Page